PD 173212Potent N-type Ca2+ channel blocker CAS# 217171-01-2 |
- AZD4547
Catalog No.:BCC3711
CAS No.:1035270-39-3
- NVP-BGJ398 phosphate
Catalog No.:BCC1814
CAS No.:1310746-10-1
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- Nintedanib (BIBF 1120)
Catalog No.:BCC3661
CAS No.:656247-17-5
- BGJ398
Catalog No.:BCC1278
CAS No.:872511-34-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 217171-01-2 | SDF | Download SDF |
| PubChem ID | 9916734 | Appearance | Powder |
| Formula | C38H53N3O3 | M.Wt | 599.85 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (166.71 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (2S)-N-[(2S)-1-(tert-butylamino)-1-oxo-3-(4-phenylmethoxyphenyl)propan-2-yl]-2-[(4-tert-butylphenyl)methyl-methylamino]-4-methylpentanamide | ||
| SMILES | CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)OCC2=CC=CC=C2)C(=O)NC(C)(C)C)N(C)CC3=CC=C(C=C3)C(C)(C)C | ||
| Standard InChIKey | GCDHMGROXQUFNR-HEVIKAOCSA-N | ||
| Standard InChI | InChI=1S/C38H53N3O3/c1-27(2)23-34(41(9)25-29-15-19-31(20-16-29)37(3,4)5)36(43)39-33(35(42)40-38(6,7)8)24-28-17-21-32(22-18-28)44-26-30-13-11-10-12-14-30/h10-22,27,33-34H,23-26H2,1-9H3,(H,39,43)(H,40,42)/t33-,34-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent N-type voltage-gated calcium channel blocker (IC50 = 36 nM). Displays selectivity over K+, Na+ and L-type Ca2+ channels. Prevents tonic seizures in the audiogenic seizure model in vivo. |
PD 173212 Dilution Calculator
PD 173212 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6671 mL | 8.3354 mL | 16.6708 mL | 33.3417 mL | 41.6771 mL |
| 5 mM | 0.3334 mL | 1.6671 mL | 3.3342 mL | 6.6683 mL | 8.3354 mL |
| 10 mM | 0.1667 mL | 0.8335 mL | 1.6671 mL | 3.3342 mL | 4.1677 mL |
| 50 mM | 0.0333 mL | 0.1667 mL | 0.3334 mL | 0.6668 mL | 0.8335 mL |
| 100 mM | 0.0167 mL | 0.0834 mL | 0.1667 mL | 0.3334 mL | 0.4168 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Etifoxine
Catalog No.:BCC1560
CAS No.:21715-46-8
- BCX 1470 methanesulfonate
Catalog No.:BCC1414
CAS No.:217099-44-0
- BCX 1470
Catalog No.:BCC1413
CAS No.:217099-43-9
- Hugorosenone
Catalog No.:BCN3776
CAS No.:217096-49-6
- Esomeprazole Magnesium trihydrate
Catalog No.:BCC1559
CAS No.:217087-09-7
- [Pyr1]-Apelin-13
Catalog No.:BCC7358
CAS No.:217082-60-5
- Apelin-17 (human, bovine)
Catalog No.:BCC5959
CAS No.:217082-57-0
- WB 4101 hydrochloride
Catalog No.:BCC6858
CAS No.:2170-58-3
- 15-Epi-Danshenol-A
Catalog No.:BCN3146
CAS No.:216987-13-2
- Shyobunone
Catalog No.:BCN4930
CAS No.:21698-44-2
- Procurcumenol
Catalog No.:BCN3555
CAS No.:21698-40-8
- Z-DL-Nva-OH
Catalog No.:BCC3304
CAS No.:21691-44-1
- Aristoliukine B
Catalog No.:BCN8096
CAS No.:217310-32-2
- Spectinomycin dihydrochloride
Catalog No.:BCC5166
CAS No.:21736-83-4
- 5-O-Demethylnobiletin
Catalog No.:BCN2958
CAS No.:2174-59-6
- 5-Methoxyresorcinol
Catalog No.:BCN6904
CAS No.:2174-64-3
- SB 268262
Catalog No.:BCC7916
CAS No.:217438-17-0
- (±)-J 113397
Catalog No.:BCC7423
CAS No.:217461-40-0
- 1-Hydroxy-2-oxopomolic acid
Catalog No.:BCN4931
CAS No.:217466-37-0
- Lucidumol A
Catalog No.:BCN8270
CAS No.:217476-73-8
- L-803,087 trifluoroacetate
Catalog No.:BCC7220
CAS No.:217480-26-7
- L-817,818
Catalog No.:BCC7221
CAS No.:217480-27-8
- Tulathromycin A
Catalog No.:BCC2019
CAS No.:217500-96-4
- Cyclo(Tyr-Val)
Catalog No.:BCN2413
CAS No.:21754-25-6
Pd-Catalyzed Regioselective 1,2-Dicarbofunctionalization of Unactivated Olefins by a Heck Reaction/Enolate Cyclization Cascade.[Pubmed:28383271]
Org Lett. 2017 Apr 21;19(8):2154-2157.
We disclose a Pd-catalyzed reaction protocol that regioselectively difunctionalizes unactivated olefins with aryl iodides and tethered enolates. The current method allows the rapid synthesis of a variety of 1,3,4-trisubstituted pyrrolidinones from simple and readily available amides. We further demonstrate this new method's application by postsynthetically modifying the arylacetic acid side chains of two commercial nonsteroidal anti-inflammatory drugs, indomethacin and tolmetin, to highly decorated 4-benzylpyrrolidinone frameworks. Mechanistic studies reveal that the reaction proceeds via a Heck reaction/enolate cyclization cascade, a process that exploits beta-H elimination in a constructive mode for regioselective 1,2-difunctionalization of unactivated olefins.
The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the 'immunoreactive' microenvironment of colorectal carcinoma.[Pubmed:28383777]
Histopathology. 2017 Sep;71(3):366-374.
AIMS: This study was designed to test programmed cell death 1 (PD-1) expression of T cells, the hallmark of T cell exhaustion, in different 'immune-classes' of colorectal carcinoma microenvironments as delineated by unsupervised hierarchical cluster analysis. METHODS AND RESULTS: A tissue microarray was made with punches from the invasive margins of 40 microsatellite-unstable and 34 microsatellite-stable colorectal carcinomas. Immune cells were phenotyped by CD8, granzyme B, CD4, FoxP3, CD68, S-100, PD-1 and programmed cell death ligand 1 (PD-L1) immunohistochemistry; tumour area per tissue spot was quantified by cytokeratin (CK)18 immunohistochemistry. For each tissue spot, intra-epithelial immune cells were counted and densities of the various immune cells were calculated. Unsupervised hierarchical cluster analysis with these data yielded a group of 'anergic/immune-naive' microenvironments (47.3%), a group of 'intermediates' (27.0%) and a group of 'immunoreactives' (25.7%) in which PD-1 expressing T cells were prominent. Sixteen of 19 tissue spots representing immunoreactive microenvironments derived from microsatellite-unstable tumours and three were from microsatellite-stable tumours. Further phenotyping of intra-epithelial T cells by sequential immunohistochemistry showed frequent granzyme B/CD8 co-expression, whereas PD-1/CD8 co-expression was more variable. Using receiver operating curve (ROC) analysis, assignment to immune classes was seen to be feasible with good sensitivity and specificity by CD8 counts only. CONCLUSION: A subset of colorectal carcinoma microenvironments is distinguished from the rest by an immune cell composition suggestive of active host anti-tumour immune defence, but this appears to be antagonized by a brisk undercurrent of T cell exhaustion. This observation may have implications for selecting colorectal carcinoma patients for immune checkpoint therapy.
Pd-catalysed ligand-enabled carboxylate-directed highly regioselective arylation of aliphatic acids.[Pubmed:28383026]
Nat Commun. 2017 Apr 6;8:14904.
alpha-amino acids bearing aromatic side chains are important synthetic units in the synthesis of peptides and natural products. Although various beta-C-H arylation methodologies for amino acid derivatives involving the assistance of directing groups have been extensively developed, syntheses that directly employ N-protected amino acids as starting materials remain rare. Herein, we report an N-acetylglycine-enabled Pd-catalysed carboxylate-directed beta-C(sp(3))-H arylation of aliphatic acids. In this way, various non-natural amino acids can be directly prepared from phthaloylalanine in one step in good to excellent yields. Furthermore, a series of aliphatic acids have been shown to be amenable to this transformation, affording beta-arylated propionic acid derivatives in moderate to good yields. More importantly, this ligand-enabled direct beta-C(sp(3))-H arylation could be easily scaled-up to 10 g under reflux conditions, highlighting the potential utility of this synthetic method.
